Alkaline Phosphatase on Health: Comparison
Please note this is a comparison between Version 4 by Haoming Wu and Version 5 by Camila Xu.

Alkaline phosphatase (ALP) is abundant in raw milk. Because of its high heat resistance, ALP negative is used as an indicator of successful sterilization. However, pasteurized milk loses its immune protection against allergies. Clinically, ALP is also used as an indicator of organ diseases. When the activity of ALP in blood increases, it is considered that diseases occur in the viscera and organs. Oral administration or injection of ALP will not cause harm to the body and has a variety of probiotic effects. For infants with low immunity, ALP intake is a good prebiotic, which can protect the infant's intestine from potential pathogens. In addition, ALP has a variety of probiotic effects on any age group, including the prevention and treatment of intestinal diseases, allergies, hepatitis, acute kidney injury (AKI), diabetes, and even the prevention of aging.

  • ALP
  • infant intestinal health
  • raw milk

1. Introduction

Alkaline phosphatase (ALP) is an enzyme that catalyses the hydrolysis of phosphate under alkaline conditions. ALP widely exists in various mammalian tissues and plays an important role in biological processes. Although human own tissues can also synthesize ALP, including tissue nonspecific alkaline phosphatase (TNAP), placental alkaline phosphatase (PLAP), germ cell alkaline phosphatase (GCALP) and intestinal alkaline phosphatase (IAP) [9]. However, for infants with incomplete immune development, ALP gene expression is still low, and exogenous ALP supplementation is very necessary[10]. At the same time, ALP protects the health and stability of tissues and bodies at all life stages. When diseases occur, ALP is used as an important biomarker for the diagnosis of many diseases [11–13].

According to clinicalkaline phosphatase (ALP) is an en diagnosis, abnormal ALP activity in blood is related to various diseases. For example, bone specific ALP and bone disease [11], breast cancer diagnosis [12]  and diabetes [13]. In case diagnosis, ALP measured in serum is used as a diagnostic tool for liver disease [14] and testicular cancer [15,16]. In patients with chronic liver disease, blood ALP increased in the order of chronic hepatitis (CH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) with pathological progress [17]. At the same time, ALP in the patient's blood will be detected before and after the medical process. The change of ALP in blood can affect the therapeutic effect and survival rate of patients, such as metastatic prostate cancer [18], metastatic breast cancer [19], clear cell chondrosarcoma [20] and metastatic nasopharyngeal carcinoma [21].

IAP activity is related to dietary nutrition and dietary frequency. Food intake can regulate the activity of IAP. Intake of omega-3 fatty acids can reduce the level of LPS and improve intestinal permeability by increasing the activity of intestinal IAP in transgenic mice [33]. In addition, protein diet may reduce the activity of IAP. When feeding calves before rumination with soybean diet, the activities of intestinal enzymes such as IAP in the intestine are reduced [34]. Another study found that the intestinal IAP activity of pigs increased significantly in the short term after using wheat or barley instead of milk based high protein diet[35]. After the protein structure of milk is destroyed by fermentation, intake of yogurt can increase the activity of IAP [36]. In addition, glucomannan, oligosaccharide and vitamin D supplementation are associated with increased intestinal IAP activity[37–39]. Some phytochemical components, such as curcumin, black pepper, red pepper, ginger, piperine and capsaicin, have also been found to be associated with increased IAP activity [40]. When mice were fasted for two days, IAP expression in the intestine decreased significantly, resulting in a decrease in the ability of intestinal LPS dephosphorylation [31]. Because starvation leads to the downregulation of IAP, the host's sensitivity to pathogens increases. Therefore, for the treatment and prognosis stage of patients, intake of diet that can increase IAP is of positive significance for the recovery of patients' health [31]. Because IAP is associated with limiting the speed of fatty acid transmembrane transport to intestinal cells [41,42]. HFD feeding increases IAP stress-induced secretion in the intestine, thereby maintaining host weight stability [43]. On the other hand, some studies have found that HFD feeding can reduce IAP activity and increase TLR4 activity in the intestine of obese rats [44]. Similarly, when present in food ω- 3 PUFA will also lead to a decrease in IAP expression and activity [45]. IAP-KO mice fed HFD were more likely to gain weight [41]. Therefore, for different individuals, the effect of HFD feeding on intestinal IAP is not stable, and further research is needed. In addition, protein intake may also be related to the regulation of IAP. The activity of ALP in the intestine of rats fed protein-free diet decreased by 36% - 38%[46]. In conclusion, the intake of food nutrition is related to the activity of ALP. Reasonable dietary intake is helpful to regulate the activity of intestinal ALP.

In Table 1, the research papers on the prevention and treatment of diseases by ALP are summarized. Relevant studies were identified byme that catalyzes the hydrolysis of phosphate under alkaline conditions. ALP wi searching Web Science, Google Scholar and PubMed. If the study meets the following criteria, it will be included in the table: 1. Study and evaluate the effect of oral or injection ALP treatment; 2. Research papers written in English until December 2021. All studies that meet the requirements of direct ALP treatment of laboratory animals are listed in the table. It turns out, the high IAP activity in the intestine of full-term newborns, coupled with the high ALP activity in breast milk in the first few days after birth, provides sufficient detoxification capacity for LPS of initially colonized bacteria [10]. After the onset of IBD in infants, TLR4 mRNA expression and protein levels in inflammatory colonic mucosa in children increased [47]. The increased expression of TLR4 may be related to the content of IAP in intestinal mucosa. IAP activity below normal level may lead to IAP/TLR4 imbalance, resulting in increased sensitivity of mucosa to LPS [25]. After treatment, the recovery of intestinal mucosa is very important for the prognosis of the disease. Therapeutic treatment to restore intestinal flora balance may have a significant impact on mucosal healing of IBD [48].  In an animal model of colitis induced by sodium dextran sulfate (DSS), exogenous administration of IAP improved the symptoms of colitis [49]. Compared with wild-type mice, IAP-KO mice had more severe colitis induced by DSS [32]. In the case of severe intestinal epithelial injury, oral IAP may have beneficial effects [50]. The results obtained in the pediatric population also demonstrate that oral IAP may be beneficial for children with IBD [25].

Early in life, the initial colonization of intestinal microorganisms will affect the development of intestinaly exists in various mammalian tissues and plays an important role host defense [51,52], and the appropriate development of intestinal tissue may have a far-reaching impact on immune health in infancy and even throughout life [53,54]. Because the intestinal immune tissue is immature at birth and develops with the initially colonized microorganisms. It has been suggested that the increase of allergy and autoimmune diseases may be caused by the interference of microbial colonization and development of intestinal host defense system [55]. It is worth noting that the host defense capacity of the intestine of preterm infants is particularly immature, and the initial colonization of intestinal microorganisms is not the same as that of normal born infants [56]. Compared with mature human intestinal cells, infant intestinal cells are more likely to produce excessive inflammatory response when stimulated, and even respond to some intestinal symbiotic bacteria with inflammatory effect [57,58]. The imbalance of intestinal microbial ecology in the neonatal period of preterm infants may lead to excessive intestinal inflammation, resulting in NEC. As the sole source of nutrition for infants, breast milk helps healthy bacterial colonization in the infant's intestines [59]. Studies have pointed out that breast milk extruded by preterm mothers can protect the infant's intestine from NEC [60,61]. Although breast milk contains many immune nutrients, such as IgA, oligosaccharides, lactoferrin, ALP, etc., it may help to prevent intestinal inflammation and NEC. At the same time, breast milk may also play an active role in stimulating health promoting bacteria, thus providing protection against NEC. Studies have pointed out that giving probiotics to preterm infants can also prevent NEC. The combination of probiotics (e.g., Lactobacillus acidophilus and Bifidobacterium bifidum) and human milk has a protective effect, but the combination of probiotics and infant formula has lost its protective effect [62,63].

Compared with in biological processes. However, human tissues can also synthesize fant formula, breast milk has several unique factors to actively protect the intestine of newborns. First, oligosaccharides in breast milk provide an energy source for the intestinal microbiota, help the growth of infant intestinal probiotics, and are beneficial to the infant intestine [64,65]. Second, breast milk itself contains a variety of bacteria that actively colonize the intestine, providing protection for the infant's primitive microbiota [66]. Third, breast milk contains immunobioactive factors, such as secretory IgA, which can change the colonization of infants' intestines and protect infants from pathogens [67,68]. Fourth, Gastrointestinal administration of exogenous IAP can improve intestinal inflammation and promote intestinal tissue regeneration, while intestinal and systemic IAP administration can reduce systemic inflammation [69]. In addition, oral IAP supplements may regulate intestinal metabolic homeostasis by stimulating intestinal IgA secretion [12]. In conclusion, breast milk can not only change the intestinal environment of infants to prevent pathogenic bacteria, but also promote the colonization of symbiotic bacteria, so as to promote the short-term and long-term immune health of the host.

IAP can maintain intestinal immune balance and improve host tolerance to symbiotic microbiota by reducing lumen ATP concentration and dephosphorylating bacterial LP, including tissue nonspecific alS [70]. At the same time, IAP knockout mice showed increased fat absorption and obesity, suggesting that the of intestinal lipid transport is related to the regulation of IAP [36]. Both endogenous and oral IAP supplementation can inhibit the absorption of LPS in dietary fat, and oral IAP supplementation can prevent and reverse metabolic syndrome. In addition, IAP supplementation improved the blood lipid status of mice fed standard low-fat food [36,71]. In animal models of intestinal injury, oral IAP reduces intestinal epithelial injury and inflammation [50]. The dynamic transformation of the form of ALP isozyme is related to the maturation of fetal intestine [72], suggesting that ALP activity may change during human fetal development. Supplementation of ALP in the intestine of newborn rat pups has a protective effect on experimentally induced NEC [73]. ALP has a protective effect on the intestine of premature young rats against intestinal damage and inflammation caused by microbial LPS [74].

Intestinal alkaline phosphatase (TNIAP), placental alkaline phos can maintain intestinal health through a variety of mechanisms: including detoxification of lipopolysaccharide (LPS), flagellin, CpG DNA and nucleotides; Up regulate the expression level of tight junction protein, thereby increasing intestinal barrier function; And regulate intestinal microbiome homeostasis [75–77]. During lactation, infant intestinal ALP gene expression and enzyme activity remain low [78]. Preterm birth and formula feeding are considered to be associated with the inhibition of IAP expression and activity, and the lack of ALP may increase the risk of NEC [79]. For infants, breast milk is the only exogenous source of ALP [10], and pasteurization destroys 99% of ALP in breast milk [80]. ALP in breast milk is considered to be an anti-inflammatory factor in neonatal intestine and a key component in inhibiting NEC [81,82]. The lack of IAP activity will lead to neonatal intestinal ecological imbalance and bacterial translocation, resulting in a variety of diseases [83].

In previous studies, it was found thatase (PLAP), germ cell alkaline phosphatase (GCALP), ant taking LPS can lead to weight gain, acute inflammation and eventually insulin resistance [84]. Similar effects can be seen in animal models fed HFD or LPS. Similarly, LPS can also lead to a pro-inflammatory response in the fetal brain after infecting the mother, thereby increasing anxiety, and reducing social activities [85]. Therefore, the researchers believe that the important roles of HFD and LPS in the pathogenesis of ASD seem to be consistent between humans and animals. ALP is considered to be a drug that can protect the balance of intestinal environment and reduce inflammation [86]. ALP has anti-inflammatory effects, prevents intestinal leakage, and promotes a healthy microbiota [70]. At the same time, recent studies have proved that oral supplementation of IAP to pregnant mothers is of positive significance to the health of infants. Mouse model test found that maternal IAP treatment can alleviate some autism spectrum disorder (ASD) like symptoms of offspring mice [87]. It is worth noting that, the content of ALP in breast milk decreased with lactation time [88]. Therefore, the intake of ALP supplementation for infants and mothers is of great significance to maintain infant health. Unfortunately, ALP does not exist in any infant formula.

Children intestinal alkaline phosphatase (growing up on farms have a lower risk of asthma and allergies than children living in the same rural area but not on farms[89,90]. This protective "farm effect" is recognized in many people until adulthood[91]. Farm exposure associated with this allergic protective effect appears to be eating unprocessed raw milk [92,93]. In particular, the consumption of raw milk and the protective effect of raw milk have nothing to do with farm conditions, so it can protect the ordinary non-agricultural population  [94,95]. Many studies have shown that eating untreated raw milk can prevent the risk of asthma and allergic diseases [92–96]. These epidemiological findings recently confirmed the causal evidence that biological milk can prevent allergic asthma caused by household dust mites and OVA induced food allergy in mouse models [97,98].

Pasteurization makes milk lose the ability to protect consumers from allergies. The histone acetylation degree of Th1 -, Th2 - and regulatory T cell related genes in splenocyte CD4+ T cells of rats treated with raw milk was higher than that of mice treated with pasteurized milk. Compared with processed milk products, the histone acetylation degree of Th2 gene in rats treated with raw milk was lower. In the study of mice allergic to food, raw milk reduced allergic symptoms to food allergens other than milk. The activation of T cell related genes is considered to be the cause of the observed tolerance induction, indicating that epigenetic modification helps raw milk protect the body from allergy [98]. On the other hand, some studies have shown that pasteurized milk lost its allergic protection, but pasteurized milk added with AP)LP restored its allergic protection[8]. Skimmed raw milk inhibited food allergy symptoms similar to raw milk, reduced acute skin allergy and low levels of OVA specific Ig-E and Th-2 related cytokines. This indicates that the fat component is not an ingredient in raw milk that inhibits food allergy [1][8].

ALP Hcan regulate the structure of intestinal microbiota and protect consumers from allergy inductiowever, for infants with incomplete immune developn. Raw milk treatment increased the relative abundance of butyrate producing bacteria in mouse intestine and Lachnospiraceae ucg-001, Lachnospiraceae ucg-008 and Ruminiclostridium 5 (Clostridium clusters xiva and IV) and decreased the relative abundance of bacterial Proteus that can promote inflammation. Clostridium clusters xiva and IV can decompose non digestible oligosaccharides to produce acetic acid, propionic acid, and butyric acid. These organisms are usually close to host epithelial cells, which has a great impact on the host immune balance [99,100]. In the study of mice intestinal microorganisms, Clostridium clusters xiva and IV can help induce the accumulation and differentiation of Foxp3 + Treg cells in mouse colon. Clostridium can induce colon epithelial cells to release active TGF- β and other Treg inducing factors, which can induce Treg differentiation by regulating CD103+ DC. In addition, Clostridium has also been shown to induce IL-10 expressing Treg cells in the colon. Increasing the colonization of intestinal Clostridium can increase the body's resistance to allergy[101]. These microbes disappeared in the intestines of mice fed pasteurized milk. However, after the addition of ALP to pasteurized milk, the changes in the intestinal probiotic microbiota observed in the raw milk treatment group reappeared and reduced allergic reactions [102].

ALP supplementat, ALP gene expression is still low, and exogenous ALion has a probiotic effect on multiple organs of the body, including the treatment of intestinal, liver and kidney related diseases[121,122]. ALP supplementation can detoxify a variety of proinflammatory mediators in the intestinal cavity. Among them, ALP has the most significant detoxification function on LPS (also known as endotoxin). In recent years, LPS has been proved to be one of the key mediators connecting the development of intestinal and liver diseases and many other systemic diseases. LPS  consists of core polysaccharide, O-antigen and lipid A. ALP can remove the phosphate group on LPS lipid A by dephosphorylation, so as to relieve the toxicity of LPS [123–125]. In the study of liver inflammation, it was found that LPS induced chronic inflammation by stimulating the expression of TLR4 in tissue cells [126,127]. When IAP gene was knocked out, the tolerance of mouse intestinal environment to LPS decreased significantly and was more vulnerable to intestinal validation[49,128]. When intestinal injury occurs, LPS is more likely to enter the blood, causing liver injury and even serious diseases. When the disease occurs, whether oral or injection, IAP supplementation is very necessarhas been widely used to prevent and treat inflammatory diseases. For example, oral administration of recombinant ALP can prevent alcohol-induced hepatic steatosis and chronic liver failure[129,130]. Although IAP may [2]be partially degraded in the stomach, oral administration after mixing IAP in drinking water is a very simple route of administration. A large number of experiments have proved that oral ALP supplementation can effectively increase the concentration of IAP in intestinal cavity [77,86].. At the same time, after IALP protects the heaP supplementation in drinking water, the concentration of serum LPS in intestinal vena cava and portal vein decreased significantly, which will greatly reduce the harm of LPS translocation to the liver, so as to further protect the liver and reduce the development of malignant inflammatory circulation and liver fibrosis[131]. In human clinical studies, duodenal and enteral IAP was administered to patients with severe ulcerative colitis for 7 days, and no human safety problems, adverse events or side effects of ALP were reported [132].

With regard to intestinal flora, ith and stability of tissues and bodies at all life stages was found that the number of intestinal bacteria in IAP-ko mice decreased overall, and oral supplementation of IAP in WT mice could quickly restore the normal intestinal flora of mice affected by antibiotics [77]. IAP prevents HFD induced metabolic endotoxemia by regulating intestinal flora [128]. In zebrafish model, zebrafish lacking IAP are highly sensitive to LPS toxicity. IAP plays a crucial role in promoting mucosal tolerance to intestinal resident bacteria [123]. Knockout of the intestinal ALP gene (AKP3) in mice leads to metabolic abnormalities, resulting in visceral fat accumulation and hepatic steatosis [133]. On the other hand, the investigation found that the endogenous IAP level of rats decreased with age, and metabolic syndrome was common in older animals [134,135]. This suggests that "IAP deficiency" may be an inducement leading to metabolic syndrome, and the oral supplementary IAP dose can be easily adjusted to achieve the purpose of preventing or treating metabolic syndrome[77].

Studies Whave demonstrated that the use of ALP in then diseases occur, ALP is used as an important bie treatment of sepsis induced AKI is promising [136–138]. In the treatment of acute renal injury, high-dose ALP (75 U/kg+25U/kg/h intravenous injection) can significantly increase serum ALP activity, making serum ALP about 5 times higher than baseline [139]. In the sheep model of sepsis, ALP can reduce inflammation and improve lung function without adverse reactions [16]. Intravenous ALP is preferentially delivered to blood and liver, kidney, and other abdominal organs at a lower dose. Therefore, in the treatment of renal injury, a high concentration of serum ALP level is required to increase the grade of renal tissue [140]. In addition, rodent model studies of isolated renal ischemia-reperfusion injury have shown that ALP treatment can reduce renal tubular injury [141].

For women arker for the diagnosis of many diseasest high risk of pregnancy complications due to LPS infection, the use of supplementary AP isozymes may be an attractive treatment option [142]. In the study of mouse model, IAP inhibited LPS to play an inflammatory role by up regulating the expression of autophagy related genes (ATG5, ATG16, IRGM1, TLR4) in mouse small intestine. Oral ALP can prevent the immune stimulation of LPS in blood to the liver. ALP can remove the phosphate group on LPS and eliminate the toxicity of LPS. At the same time, ALP can reduce TLR4 ,TNF-a, matured IL-1β and NF- κB expression by up regulating the level of mir146a in mouse liver tissue in turn reduces the inflammatory response of the liver [143]. It was found that endogenous IAP decreased during liver fibrosis, resulting in intestinal barrier dysfunction and fibrosis deterioration. Oral IAP can protect the intestinal [3][4][5]barrier and further prevent the development of liver fibrosis through TLR4 mediated mechanism [131]. Although the mechanism is unclear, oral, and intravenous ALP play a renal protective role in various sepsis animal models [16,129,144,145].

2. Important Health Indicators

According to clinical diagnosis, abnormal ALP activity in blood is related to various diseases—for example, bone-specific ALP and bone disease [3], breast cancer diagnosis [4], and diabetes [5]. In the case of diagnosis, ALP measured in serum is used as a diagnostic tool for liver disease [6] and testicular cancer [7][8]. In patients with chronic liver disease, blood ALP increased in the order of chronic hepatitis (CH), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) with pathological progress [9]. At the same time, ALP in the patient’s blood will be detected before and after a medical process. The change in ALP in blood can affect the therapeutic effect and survival rate of patients, such as metastatic prostate cancer [10], metastatic breast cancer [11], clear cell chondrosarcoma [12], and metastatic nasopharyngeal carcinoma [13].

3. Factors Affecting ALP Activity

IAP has an important protective effect on the infant intestine. IAP is a homodimer, and each subunit consists of two Zn2+ and one Mg2+ ion [14]. The activity of IAP was the highest at pH 9.7 [15]. IAP is generally secreted in the duodenum, followed by less expression in the jejunum, ileum, and colon [16][17][18]. IAP is largely absent in the stomach in an acidic environment [18][19]. IAP mainly exists in lumen vesicles secreted by intestinal cells on the brush edge of microvilli. At the same time, a small amount of IAP will also be bidirectionally released into the blood and lumen and then spread throughout the intestine [20]. The investigation found that the level of IAP activity in human intestinal tract varies with blood type. The level of IAP in human intestinal tract of type O and type B is the highest, while the activity in human intestinal tract of type A blood is the lowest [21]. In the gut, IAP is a mucosal defense factor that restricts bacteria from crossing the mucosal barrier into mesenteric lymph nodes [22][23]. In addition to the local activity of IAP in intestinal mucosa, about 1–2% of IAP is released into the blood or gastrointestinal cavity to treat and prevent systemic infection and sepsis [24].
IAP activity is related to dietary nutrition and dietary frequency. Food intake can regulate the activity of IAP. Intake of omega-3 fatty acids can reduce the level of LPS and improve intestinal permeability by increasing the activity of intestinal IAP in transgenic mice [25]. In addition, a protein diet may reduce the activity of IAP. When feeding calves before rumination with a soybean diet, the activities of intestinal enzymes such as IAP in the intestine are reduced [26]. Another study found that the intestinal IAP activity of pigs increased significantly in the short term after using wheat or barley instead of a milk-based high protein diet [27]. After the protein structure of milk is destroyed by fermentation, intake of yogurt can increase the activity of IAP [28]. In addition, glucomannan, oligosaccharide, and vitamin D supplementation are associated with increased intestinal IAP activity [29][30][31]. Some phytochemical components, such as curcumin, black pepper, red pepper, ginger, piperine, and capsaicin, have also been found to be associated with increased IAP activity [32]. When mice were fasted for two days, IAP expression in the intestine decreased significantly, resulting in a decrease in the ability of intestinal LPS dephosphorylation [23]. Because starvation leads to the downregulation of IAP, the host’s sensitivity to pathogens increases. Therefore, for the treatment and prognosis stage of patients, intake of diet that can increase IAP is of positive significance for the recovery of patients’ health [23] because IAP is associated with limiting the speed of fatty acid transmembrane transport to intestinal cells [33][34]. HFD feeding increases IAP stress-induced secretion in the intestine, thereby maintaining host weight stability [35]. On the other hand, some studies have found that HFD feeding can reduce IAP activity and increase TLR4 activity in the intestine of obese rats [36]. Similarly, when present in food ω- 3 PUFA will also lead to a decrease in IAP expression and activity [37]. IAP-KO mice fed HFD were more likely to gain weight [33]. Therefore, for different individuals, the effect of HFD feeding on intestinal IAP is not stable, and further research is needed. In addition, protein intake may also be related to the regulation of IAP. The activity of ALP in the intestine of rats fed a protein-free diet decreased by 36–38% [38]. In conclusion, the intake of food nutrition is related to the activity of ALP. Reasonable dietary intake is helpful for regulating the activity of intestinal ALP.

4. Infant Intestinal Health

In Table 1, the research on the prevention and treatment of diseases by ALP are summarized. Relevant studies were identified by searching Web Science, Google Scholar, and PubMed. If a study met the following criteria, it was included in the table: 1. Study and evaluate the effect of oral or injection ALP treatment; 2. Researches  written in English until December 2021. All studies that met the requirements of direct ALP treatment of laboratory animals are listed in the table. It turns out that high IAP activity in the intestine of full-term newborns, coupled with the high ALP activity in breast milk in the first few days after birth, provides sufficient detoxification capacity for LPS of initially colonized bacteria [2]. After the onset of IBD in infants, TLR4 mRNA expression and protein levels in inflammatory colonic mucosa in children increased [39]. The increased expression of TLR4 may be related to the content of IAP in intestinal mucosa. IAP activity below normal level may lead to IAP/TLR4 imbalance, resulting in increased sensitivity of mucosa to LPS [17]. After treatment, the recovery of intestinal mucosa is very important for the prognosis of the disease. Therapeutic treatment to restore intestinal flora balance may have a significant impact on mucosal healing of IBD [40]. In an animal model of colitis induced by sodium dextran sulfate (DSS), exogenous administration of IAP improved the symptoms of colitis [41]. Compared with wild-type mice, IAP-KO mice had more severe colitis induced by DSS [24]. In the case of severe intestinal epithelial injury, oral IAP may have beneficial effects [42]. The results obtained in the pediatric population also demonstrate that oral IAP may be beneficial for children with IBD [17].
Early in life, the initial colonization of intestinal microorganisms will affect the development of intestinal host defense [43][44], and the appropriate development of intestinal tissue may have a far-reaching impact on immune health in infancy and even throughout life [45][46]. Because the intestinal immune tissue is immature at birth and develops with the initially colonized microorganisms, it has been suggested that the increase in allergy and autoimmune diseases may be caused by the interference of microbial colonization and development of intestinal host defense system [47]. It is worth noting that the host defense capacity of the intestine of preterm infants is particularly immature and that the initial colonization of intestinal microorganisms is not the same as that of normal-born infants [48]. Compared with mature human intestinal cells, infant intestinal cells are more likely to produce excessive inflammatory response when stimulated and even respond to some intestinal symbiotic bacteria with an inflammatory effect [49][50]. The imbalance in intestinal microbial ecology in the neonatal period of preterm infants may lead to excessive intestinal inflammation, resulting in NEC. As the sole source of nutrition for infants, breast milk helps healthy bacterial colonization in the infant’s intestines [51]. Studies have pointed out that breast milk extruded by preterm mothers can protect the infant’s intestine from NEC [52][53]. Although breast milk contains many immune nutrients, such as IgA, oligosaccharides, lactoferrin, ALP, etc., it may help to prevent intestinal inflammation and NEC. At the same time, breast milk may also play an active role in stimulating health-promoting bacteria, thus providing protection against NEC. Studies have pointed out that giving probiotics to preterm infants can also prevent NEC. The combination of probiotics (e.g., Lactobacillus acidophilus and Bifidobacterium bifidum) and human milk has a protective effect, but the combination of probiotics and infant formula has lost its protective effect [54][55].
Compared with infant formula, breast milk has several unique factors to actively protect the intestine of newborns. First, oligosaccharides in breast milk provide an energy source for the intestinal microbiota, help the growth of infant intestinal probiotics, and are beneficial to the infant intestine [56][57]. Second, breast milk itself contains a variety of bacteria that actively colonize the intestine, providing protection for the infant’s primitive microbiota [58]. Third, breast milk contains immunobioactive factors, such as secretory IgA, which can change the colonization of infants’ intestines and protect infants from pathogens [59][60]. Fourth, gastrointestinal administration of exogenous IAP can improve intestinal inflammation and promote intestinal tissue regeneration, while intestinal and systemic IAP administration can reduce systemic inflammation [61]. In addition, oral IAP supplements may regulate intestinal metabolic homeostasis by stimulating intestinal IgA secretion [4]. In conclusion, breast milk not only can change the intestinal environment of infants to prevent pathogenic bacteria but also can promote the colonization of symbiotic bacteria, so as to promote the short-term and long-term immune health of the host.
IAP can maintain intestinal immune balance and improve host tolerance to symbiotic microbiota by reducing lumen ATP concentration and dephosphorylating bacterial LPS [62]. At the same time, IAP knockout mice showed increased fat absorption and obesity, suggesting that intestinal lipid transport is related to the regulation of IAP [28]. Both endogenous and oral IAP supplementation can inhibit the absorption of LPS in dietary fat, and oral IAP supplementation can prevent and reverse metabolic syndrome. In addition, IAP supplementation improved the blood lipid status of mice fed standard low-fat food [28][63]. In animal models of intestinal injury, oral IAP reduces intestinal epithelial injury and inflammation [42]. The dynamic transformation of the form of ALP isozyme is related to the maturation of fetal intestine [64], suggesting that ALP activity may change during human fetal development. Supplementation of ALP in the intestine of newborn rat pups has a protective effect on experimentally induced NEC [65]. ALP has a protective effect on the intestine of premature young rats against intestinal damage and inflammation caused by microbial LPS [66].
Intestinal alkaline phosphatase (IAP) can maintain intestinal health through a variety of mechanisms, including detoxification of lipopolysaccharide (LPS), flagellin, CpG DNA and nucleotides; upregulation of the expression level of tight junction protein, thereby increasing intestinal barrier function; and regulation of intestinal microbiome homeostasis [67][68][69]. During lactation, infant intestinal ALP gene expression and enzyme activity remain low [70]. Preterm birth and formula feeding are considered to be associated with the inhibition in IAP expression and activity, and the lack of ALP may increase the risk of NEC [71]. For infants, breast milk is the only exogenous source of ALP [2], and pasteurization destroys 99% of ALP in breast milk [72]. ALP in breast milk is considered to be an anti-inflammatory factor in the neonatal intestine and a key component in inhibiting NEC [73][74]. The lack of IAP activity will lead to neonatal intestinal ecological imbalance and bacterial translocation, resulting in a variety of diseases [75].
In previous studies, it was found that taking LPS can lead to weight gain and acute inflammation and eventually insulin resistance [76]. Similar effects can be seen in animal models fed HFD or LPS. Similarly, LPS can also lead to a pro-inflammatory response in the fetal brain after infecting the mother, thereby increasing anxiety and reducing social activities [77]. Therefore, researchers believe that the important roles of HFD and LPS in the pathogenesis of ASD seem to be consistent between humans and animals. ALP is considered to be a drug that can protect the balance in the intestinal environment and reduce inflammation [78]. ALP has anti-inflammatory effects, prevents intestinal leakage, and promotes a healthy microbiota [62]. At the same time, recent studies have proved that oral supplementation of IAP to pregnant mothers is of positive significance to the health of infants. A mouse model test found that maternal IAP treatment can alleviate some autism spectrum disorder (ASD)-like symptoms of offspring mice [79]. It is worth noting that the content of ALP in breast milk decreased with lactation time [80]. Therefore, the intake of ALP supplementation for infants and mothers is of great significance for maintaining infant health. Unfortunately, ALP does not exist in any infant formula.

5. Inhibition of Allergy

Children growing up on farms have a lower risk of asthma and allergies than children living in the same rural area but not on farms [81][82]. This protective “farm effect” is recognized in many people until adulthood [83]. The farm exposure associated with this allergic protective effect appears to be eating unprocessed raw milk [84][85]. In particular, the consumption of raw milk and the protective effect of raw milk have nothing to do with farm conditions, so it can protect the ordinary non-agricultural population [86][87]. Many studies have shown that eating untreated raw milk can prevent the risk of asthma and allergic diseases [84][85][86][87][88]. These epidemiological findings recently confirmed the causal evidence that biological milk can prevent allergic asthma caused by household dust mites and OVA-induced food allergy in mouse models [89][90].
Pasteurization makes milk lose the ability to protect consumers from allergies. The histone acetylation degree of Th1-, Th2-, and regulatory T cell-related genes in splenocyte CD4+ T cells of rats treated with raw milk was higher than that of mice treated with pasteurized milk. Compared with processed milk products, the histone acetylation degree of Th2 gene in rats treated with raw milk was lower. In the research of mice allergic to food, raw milk reduced allergic symptoms to food allergens other than milk. The activation of T cell-related genes is considered to be the cause of the observed tolerance induction, indicating that epigenetic modification helps raw milk protect the body from allergy [90]. On the other hand, some studies have shown that pasteurized milk lost its allergic protection, but pasteurized milk added with ALP restored its allergic protection [91]. Skimmed raw milk inhibited food allergy symptoms similar to raw milk and reduced acute skin allergy and lowered levels of OVA-specific Ig-E- and Th-2-related cytokines. This indicates that the fat component is not an ingredient in raw milk that inhibits food allergy [91].
ALP can regulate the structure of intestinal microbiota and protect consumers from allergy induction. Raw milk treatment increased the relative abundance of butyrate producing bacteria in mouse intestine, in addition to increasing Lachnospiraceae ucg-001, Lachnospiraceae ucg-008, and Ruminiclostridium 5 (Clostridium clusters xiva and IV), and decreased the relative abundance of bacterial Proteus that can promote inflammation. Clostridium clusters xiva and IV can decompose nondigestible oligosaccharides to produce acetic acid, propionic acid, and butyric acid. These organisms are usually close to host epithelial cells, which have a great impact on the host immune balance [92][93]. In a study of mice intestinal microorganisms, Clostridium clusters xiva and IV can help induce the accumulation and differentiation of Foxp3 + Treg cells in mouse colon. Clostridium can induce colon epithelial cells to release active TGF-β and other Treg inducing factors, which can induce Treg differentiation by regulating CD103+ DC. In addition, Clostridium has also been shown to induce IL-10 expressing Treg cells in the colon. Increasing the colonization of intestinal Clostridium can increase the body’s resistance to allergy [94]. These microbes disappeared in the intestines of mice fed pasteurized milk. However, after the addition of ALP to pasteurized milk, the changes in the intestinal probiotic microbiota observed in the raw milk treatment group reappeared and reduced allergic reactions [95].

6. Other Diseases

ALP supplementation has a probiotic effect on multiple organs of the body, including the treatment of intestinal-, liver-, and kidney-related diseases [96][97]. ALP supplementation can detoxify a variety of proinflammatory mediators in the intestinal cavity. Among them, ALP has the most significant detoxification function on LPS (also known as endotoxin). In recent years, LPS has been proved to be one of the key mediators connecting the development of intestinal and liver diseases and many other systemic diseases. LPS consists of core polysaccharide, O-antigen, and lipid A. ALP can remove the phosphate group on LPS lipid A by dephosphorylation, so as to relieve the toxicity of LPS [98][99][100]. In a study of liver inflammation, it was found that LPS induced chronic inflammation by stimulating the expression of TLR4 in tissue cells [101][102]. When the IAP gene was knocked out, the tolerance of mouse intestinal environment to LPS decreased significantly and was more vulnerable to intestinal validation [41][63]. When intestinal injury occurs, LPS is more likely to enter the blood, causing liver injury and even serious diseases. When disease occurs, IAP supplementation—whether oral or injection—has been widely used to prevent and treat inflammatory diseases. For example, oral administration of recombinant ALP can prevent alcohol-induced hepatic steatosis and chronic liver failure [103][104]. Although IAP may be partially degraded in the stomach, oral administration after mixing IAP in drinking water is a very simple route of administration. A large number of experiments have proved that oral ALP supplementation can effectively increase the concentration of IAP in the intestinal cavity [69][78]. At the same time, after IAP supplementation in drinking water, the concentration of serum LPS in intestinal vena cava and portal vein decreased significantly, which will greatly reduce the harm of LPS translocation to the liver, so as to further protect the liver and reduce the development of malignant inflammatory circulation and liver fibrosis [105]. In human clinical studies, duodenal and enteral IAP was administered to patients with severe ulcerative colitis for 7 days, and no human safety problems, adverse events, or side effects of ALP were reported [106].
With regard to intestinal flora, it was found that the number of intestinal bacteria in IAP-ko mice decreased overall and that oral supplementation of IAP in WT mice could quickly restore the normal intestinal flora of mice affected by antibiotics [69]. IAP prevents HFD-induced metabolic endotoxemia by regulating intestinal flora [63]. In a zebrafish model, zebrafish lacking IAP are highly sensitive to LPS toxicity. IAP plays a crucial role in promoting mucosal tolerance to intestinal resident bacteria [98]. Knockout of the intestinal ALP gene (AKP3) in mice leads to metabolic abnormalities, resulting in visceral fat accumulation and hepatic steatosis [107]. On the other hand, an investigation found that the endogenous IAP level of rats decreased with age and that metabolic syndrome was common in older animals [108][109]. This suggests that “IAP deficiency” may be an inducement leading to metabolic syndrome and that the oral supplementary IAP dose can be easily adjusted to achieve the purpose of preventing or treating metabolic syndrome [69].
Studies have demonstrated that the use of ALP in the treatment of sepsis-induced AKI is promising [110][111][112]. In the treatment of acute renal injury, high-dose ALP (75 U/kg + 25 U/kg/h intravenous injection) can significantly increase serum ALP activity, making serum ALP about 5 times higher than baseline [113]. In a sheep model of sepsis, ALP can reduce inflammation and improve lung function without adverse reactions [8]. Intravenous ALP is preferentially delivered to blood and to liver, kidney, and other abdominal organs at a lower dose. Therefore, in the treatment of renal injury, a high concentration of serum ALP level is required to increase the grade of renal tissue [114]. In addition, rodent model studies of isolated renal ischemia-reperfusion injury have shown that ALP treatment can reduce renal tubular injury [115].
For women at high risk of pregnancy complications due to LPS infection, the use of supplementary AP isozymes may be an attractive treatment option [116]. In a mouse model study, IAP inhibited LPS to play an inflammatory role by upregulating the expression of autophagy-related genes (ATG5, ATG16, IRGM1, TLR4) in the mouse small intestine. Oral ALP can prevent the immune stimulation of LPS in blood to the liver. ALP can remove the phosphate group on LPS and eliminate the toxicity of LPS. At the same time, ALP can reduce TLR4, TNF-a, matured IL-1β, and NF-κB expression by upregulating the level of mir146a in mouse liver tissue, which in turn reduces the inflammatory response of the liver [117]. It was found that endogenous IAP decreased during liver fibrosis, resulting in intestinal barrier dysfunction and fibrosis deterioration. Oral IAP can protect the intestinal barrier and further prevent the development of liver fibrosis through a TLR4-mediated mechanism [107]. Although the mechanism is unclear, oral and intravenous ALP play a renal protective role in various sepsis animal models [8][105][118][119].
T. Preventive and therapeutic effects of alkable 1.ine phosphatase (ALP) on Preventive and therapeutic effects of alkaline phosphatase (ALP) on diseases.

diseases

 

Animal

Treatment method

Treatment dosage

Treatment frequency

Duration

Disease

Description

Reference

Rats

Oral

Base formula

Feed

4 days

NEC

Protect intestine

[164]

Rats

Oral

0.4, 4 or 40 U/kg

Feed

3 days

NEC

Preserving the intestinal epithelial barrier function

[165]

Rats

Oral

0.4, 4 or 40 U/kg

Feed

1 day

NEC

Decreased nitrosative stress; decreased intestinal TNF-α mRNA expression; decreased LSP translocation into the serum

[166]

Rats

Oral

0.4, 4 or 40 U/kg

Feed

1 day

NEC

Reduces systemic proinflammatory cytokine expression

[167]

Rats

Oral

700 U/kg

Gastroesophageal catheter

6 days

IBD

Protection against bacterial translocation

[30]

Rats

Oral

1035 U

Drinking water

8 days

IBD

Reduced mRNA levels for TNF-α, IL-1β, IL-6 and iNOS

[26]

Mice

Oral

200 U/kg

Gavage

4 hours

Liver injury

Reducing LPS toxicity and preventing liver injury

[143]

Mice

Oral

6 U/ml

Gavage

8 days

Food Allergic

Reduction of CD103+CD11b+ dendritic cells and TGF-β-producing regulatory T cells in the mesenteric lymph nodes

[8]

Mice

Oral

6 U/ml

Gavage

8 days

Food Allergic

Regulation of intestinal microbial community structure

[102]

Mice

Oral

100 or 300 U

Gavage

2 weeks

chronic colitis

Inhibit the activation of intestinal epithelial cells and peritoneal macrophages, and attenuate chronic murine colitis

[168]

Mice

Oral

100 U/ml

Drinking water

21 days

Metabolic syndrome

Alterations in the composition of the gut microbiota

[119]

Mice

Oral

150 or 300 U/ml

Drinking water

48 hours

Gut barrier dysfunction

Decreased expression of intestinal junctional proteins and impaired barrier function

[116]

Mice

Oral

200 U/ml

Drinking water

5 days

Bacterial infections

Protected mice from antibiotic-associated bacterial infections

[117]

Mice

Oral

100 U/ml

Drinking water

11 weeks

metabolic syndrome

Inhibits absorption of endotoxin with dietary fat; prevents reverses metabolic syndrome

[128]

Mice

Oral

300 U/ml

Drinking water

7 days

Inflammatory bowel diseases

Tissue myeloperoxidase activity and proinflammatory cytokines were significantly decreased

[49]

Mice

Oral

200 U/ml

Drinking water

4 days

liver fibrosis

Protects the gut barrier and development of liver fibrosis via a TLR4-mediated mechanism.

[131]

Mice

Oral

100 U/ml

Drinking water

Lifetime

aging

Targeting crucial intestinal alterations, including gut barrier dysfunction, microbiome dysbiosis, and endotoxemia

[86]

Mice

Oral

200 U/ml

Liquid diet

10 days

Hepatosteatosis

Ameliorated the activation of hepatic stellate cells and prevented their lipogenic effect on hepatocytes

[129]

Human

Oral

30,000 U

infusion pump

7 days

Ulcerative Colitis

Decrease the C-reactive protein and stool calprotectin levels

[132]

Rats

injection

1000 U/kg

intraperitoneal

4 days

Acute liver failure

Reduced LPS activity and Hepatic TLR4 expression

[130]

Rats

injection

1000 U/kg

intraperitoneal

24 hours

Acute kidney injury

Reduce renal inflammation; dephosphorylation of ATP and LPS

[144]

Rats

injection

500 U/kg

intraperitoneal

5 min

partial liver resection

Attenuate both hepatic and pulmonary injury

[169]

Mice

injection

100 U/ml

Intestinal loop

2 hours

Intestinal flora disorder

Inhibiting the concentration of luminal nucleotide triphosphates

[114]

Mice

injection

15 U/ml

Intravenous

1 day

Sepsis

Normalize Body temperature

[170]

Mice

injection

150 U

intravenous

5 min

Pregnancy complications

Protects Early pregnancy Defects

[142]

Mice

injection

150 U/kg

intravenous

72 hours

Secondary Peritonitis

Attenuates the inflammatory response both locally and systemically and reduces associated liver and lung damage

[171]

Human

injection

5.6 U/kg/h

Intravenous

36 hours

cardiac surgery

Endogenous alkaline phosphatase release

[172]

Human

injection

67.5 U/kg+132.5 U/kg/24 h

Intravenous

48 hours

Acute kidney injury

Reductions in the systemic markers C-reactive protein, IL-6, LPS-binding protein and in the urinary excretion of Kidney Injury Molecule-1 and IL-18

[137]

Piglet

injection

1, 5, or 25 U/kg/h

Intravenous

4 hours

Acute kidney injury

Increased serum or renal tissue AP activity

[139]

Piglet

injection

1, 5, or 25 U/kg/h

Intravenous

4 hours

Cardiac surgery

Increased kidney and liver tissue alkaline phosphatase activity

[173]

AnimalTreatment MethodTreatment DosageTreatment FrequencyDurationDiseaseDescriptionReference
RatsOralBase formulaFeed4 daysNECProtect intestine[120]
RatsOral0.4, 4,or 40 U/kgFeed3 daysNECPreserving the intestinal epithelial barrier function[121]
RatsOral0.4, 4, or 40 U/kgFeed1 dayNECDecreased nitrosative stress; decreased intestinal TNF-α mRNA expression; decreased LSP translocation into the serum[122]
RatsOral0.4, 4, or 40 U/kgFeed1 dayNECReduces systemic proinflammatory cytokine expression[123]
RatsOral700 U/kgGastroesophageal catheter6 daysIBDProtection against bacterial translocation[22]
RatsOral1035 UDrinking water8 daysIBDReduced mRNA levels for TNF-α, IL-1β, IL-6, and iNOS[18]
MiceOral200 U/kgGavage4 hLiver injuryReducing LPS toxicity and preventing liver injury[117]
MiceOral6 U/mlGavage8 daysFood allergicReduction in CD103+CD11b+ dendritic cells and TGF-β-producing regulatory T cells in the mesenteric lymph nodes[91]
MiceOral6 U/mlGavage8 daysFood allergicRegulation of intestinal microbial community structure[95]
MiceOral100 or 300 UGavage2 weeksChronic colitisInhibit the activation of intestinal epithelial cells and peritoneal macrophages and attenuate chronic murine colitis[124]
MiceOral100 U/mLDrinking water21 daysMetabolic syndromeAlterations in the composition of the gut microbiota[125]
MiceOral150 or 300 U/mLDrinking water48 hGut barrier dysfunctionDecreased expression of intestinal junctional proteins and impaired barrier function[126]
MiceOral200 U/mLDrinking water5 daysBacterial infectionsProtected mice from antibiotic-associated bacterial infections[127]
MiceOral100 U/mLDrinking water11 weeksMetabolic syndromeInhibits absorption of endotoxin with dietary fat; prevents or reverses metabolic syndrome[63]
MiceOral300 U/mLDrinking water7 daysInflammatory bowel diseasesTissue myeloperoxidase activity and proinflammatory cytokines were significantly decreased[41]
MiceOral200 U/mLDrinking water4 daysLiver fibrosisProtects the gut barrier and development of liver fibrosis via a TLR4-mediated mechanism[105]
MiceOral100 U/mLDrinking waterLifetimeAgingTargeting crucial intestinal alterations, including gut barrier dysfunction, microbiome dysbiosis, and endotoxemia[78]
MiceOral200 U/mLLiquid diet10 daysHepatosteatosisAmeliorated the activation of hepatic stellate cells and prevented their lipogenic effect on hepatocytes[105]
HumanOral30,000 UInfusion pump7 daysUlcerative colitisDecrease the C-reactive protein and stool calprotectin levels[106]
RatsInjection1000 U/kgIntraperitoneal4 daysAcute liver failureReduced LPS activity and hepatic TLR4 expression[104]
RatsInjection1000 U/kgIntraperitoneal24 hAcute kidney injuryReduce renal inflammation; dephosphorylation of ATP and LPS[118]
RatsInjection500 U/kgIntraperitoneal5 minPartial liver resectionAttenuate both hepatic and pulmonary injury[128]
MiceInjection100 U/mLIntestinal loop2 hIntestinal flora disorderInhibiting the concentration of luminal nucleotide triphosphates[129]
MiceInjection15 U/mLIntravenous1 daySepsisNormalize body temperature[130]
MiceInjection150 UIntravenous5 minPregnancy complicationsProtects early pregnancy defects[116]
MiceInjection150 U/kgIntravenous72 hSecondary peritonitisAttenuates the inflammatory response both locally and systemically and reduces associated liver and lung damage[131]
HumanInjection5.6 U/kg/hIntravenous36 hCardiac surgeryEndogenous alkaline phosphatase release[132]
HumanInjection67.5 U/kg + 132.5 U/kg/24 hIntravenous48 hAcute kidney injuryReductions in the systemic markers C-reactive protein, IL-6, and LPS-binding protein and in the urinary excretion of kidney injury molecule-1 and IL-18[111]
PigletInjection1, 5, or 25 U/kg/hIntravenous4 hAcute kidney injuryIncreased serum or renal tissue AP activity[113]
PigletInjection1, 5, or 25 U/kg/hIntravenous4 hCardiac surgeryIncreased kidney and liver tissue alkaline phosphatase activity[133]

 

Video Production Service